TL;DR
Wegovy (semaglutide 2.4mg) causes gastrointestinal side effects in the majority of patients. In the STEP-1 trial (NCT03548935), nausea affected 44% of participants on the maintenance dose compared to 18% on placebo. About 7% of patients discontinued due to GI side effects.
Serious events like pancreatitis occur in fewer than 1%, while gallbladder events affect roughly 2.6%.
Wegovy was the first semaglutide product approved by the FDA specifically for chronic weight management, earning approval in June 2021 based on the STEP clinical trial program. The STEP trials enrolled over 4,500 participants and generated the largest safety data available for semaglutide at the 2.4mg weight-loss dose. This guide covers every documented side effect with exact frequencies, practical management strategies, and clear guidance on when to contact your doctor.
All data here references the STEP-1 trial (NCT03548935) and the Wegovy prescribing information unless otherwise noted. Understanding these numbers helps you set realistic expectations and work with your provider to minimize discomfort.
What Are the Most Common Wegovy Side Effects?
The most common Wegovy side effects are gastrointestinal, with nausea affecting 44% of patients on the 2.4mg maintenance dose in the STEP-1 trial (NCT03548935), compared to 18% on placebo. Diarrhea affected 30%, vomiting 24%, and constipation 24%. These rates are notably higher than those seen with lower semaglutide doses used for diabetes (Ozempic), because Wegovy uses a higher dose optimized for weight loss.
Semaglutide works by activating GLP-1 receptors, which slow gastric emptying and reduce appetite. The GI side effects are a direct consequence of this mechanism. Most patients find that symptoms peak during the dose-escalation phase and improve once they reach the maintenance dose and their body fully adjusts.
| Side Effect | Wegovy 2.4mg | Placebo | Typical Onset | Typical Resolution |
|---|---|---|---|---|
| Nausea | 44% | 18% | Week 1 to 2 after dose change | 4 to 8 weeks |
| Diarrhea | 30% | 16% | Week 1 to 3 | 2 to 6 weeks |
| Vomiting | 24% | 6% | Week 1 to 2 after dose change | 2 to 4 weeks |
| Constipation | 24% | 11% | Week 2 to 4 | Ongoing for some |
| Headache | 14% | 10% | Week 1 to 2 | 2 to 4 weeks |
| Abdominal pain | 11% | 7% | Variable | 2 to 6 weeks |
| Fatigue | 6% | 4% | Week 1 to 3 | 4 to 6 weeks |
| Dyspepsia | 6% | 3% | After meals | 4 to 6 weeks |
| Dizziness | 5% | 3% | Week 1 to 2 | 2 to 4 weeks |
| Bloating | 4% | 2% | Week 1 to 3 | 4 to 8 weeks |
| Gastroesophageal reflux | 4% | 2% | Variable | 4 to 8 weeks |
| Flatulence | 4% | 2% | Week 1 to 3 | 4 to 6 weeks |
| Hair loss | 3% | 1% | Month 3 to 6 | Stabilizes by month 9 to 12 |
The GI discontinuation rate of approximately 7% in STEP-1 is a key number. It means that while most patients experience some GI discomfort, the vast majority (93%) find it manageable enough to continue treatment. Among those who do complete the full escalation, side effects typically become much milder once the body adjusts to the maintenance dose.
What Are the Serious Side Effects and Warning Signs?
Serious side effects from Wegovy are uncommon but can be medically significant. In the STEP-1 trial (NCT03548935), gallbladder events occurred in 2.6% of semaglutide-treated patients compared to 1.2% on placebo, making this the most notable serious adverse event. Pancreatitis was reported in fewer than 1% of participants.
Like all GLP-1 receptor agonists, Wegovy carries a boxed warning about thyroid C-cell tumors based on rodent studies. For a complete cost breakdown, see our cheapest semaglutide options.
Gallbladder Events (2.6%)
Gallstones and cholecystitis were the most common serious adverse events in the STEP program, reported in 2.6% of Wegovy patients versus 1.2% on placebo. Rapid weight loss is a known independent risk factor for gallstone formation, so this elevated rate is partially expected. The risk appears highest during the first 6 to 12 months of treatment when weight loss is most rapid.
Warning signs include severe pain in the upper right abdomen or center of the abdomen, pain that radiates to the right shoulder or back, nausea and vomiting unrelated to eating, fever, and yellowing of the skin or eyes. Seek medical attention promptly if these symptoms appear.
Pancreatitis (fewer than 1%)
Acute pancreatitis was reported in fewer than 1% of STEP trial participants. The presenting symptom is typically severe, persistent pain in the upper abdomen that radiates to the back, accompanied by nausea and vomiting that does not improve with standard remedies. If you suspect pancreatitis, stop taking Wegovy immediately and seek emergency medical care.
Patients with a history of pancreatitis should discuss the risk-benefit calculation with their provider before starting Wegovy. Alcohol use and very high triglyceride levels increase the background risk of pancreatitis.
Thyroid C-Cell Tumors (Boxed Warning)
Wegovy carries an FDA boxed warning based on rodent studies showing that semaglutide caused dose-dependent thyroid C-cell tumors in rats and mice. This effect has not been confirmed in humans, and the relevance to human biology remains unclear. However, Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Monitor for symptoms including a lump or swelling in the neck, hoarseness, difficulty swallowing, and shortness of breath. Report any of these to your healthcare provider promptly.
Hypoglycemia in Patients with Type 2 Diabetes
While Wegovy is approved for weight management (not diabetes), some patients with type 2 diabetes use it off-label or alongside other glucose-lowering medications. In these cases, the risk of hypoglycemia increases significantly, especially when combined with insulin or sulfonylureas. Dose adjustments to existing diabetes medications are usually necessary.
Kidney Injury
Cases of acute kidney injury have been reported with Wegovy, primarily in patients who experienced significant dehydration from persistent vomiting or diarrhea. Patients with pre-existing chronic kidney disease are at higher risk. Maintaining adequate hydration is critical, especially during dose escalation and GI symptom flares.
How Can You Manage Wegovy Side Effects?
The STEP trial investigators and obesity medicine specialists have developed practical strategies for managing Wegovy's GI side effects. The single most important factor is following the recommended 4-week dose-escalation schedule, which gives the body time to adjust at each level. Approximately 17 weeks are needed to reach the full 2.4mg maintenance dose from the 0.25mg starting dose.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Managing Nausea (44% of patients)
Eat smaller portions spread across 4 to 6 mini-meals per day. Prioritize bland, easy-to-digest foods like rice, toast, crackers, lean chicken, and bananas. Avoid strong-smelling foods, cooking odors, and lying flat after eating.
Staying upright for at least 30 minutes after meals helps reduce nausea.
Ginger supplements, ginger tea, and peppermint tea have evidence supporting their anti-nausea properties. For more severe nausea, your provider may prescribe ondansetron (Zofran) or promethazine to bridge you through the adjustment period. Some patients find that injecting in the evening, right before bed, helps them sleep through the worst nausea window.
Managing Diarrhea (30% of patients)
Hydration is the top priority. Drink fluids with electrolytes (sports drinks, broth, or electrolyte packets) to replace what you lose. Reduce fiber intake temporarily if diarrhea is acute, as high fiber can make it worse.
Avoid dairy, artificial sweeteners, caffeine, and greasy foods during flare-ups.
Over-the-counter loperamide (Imodium) is safe for short-term use if diarrhea is frequent or disruptive. If it persists beyond 2 to 3 weeks at the same dose, talk to your provider. Persistent diarrhea with dehydration can lead to kidney injury, so do not ignore it.
Managing Vomiting (24% of patients)
Vomiting usually occurs when eating too much, eating too quickly, or eating high-fat foods. The key strategy is to eat slowly, chew thoroughly, and stop as soon as you feel any fullness. Your stomach empties more slowly on Wegovy, so your pre-medication portion sizes will be too large.
If vomiting is persistent and prevents you from keeping fluids down for more than 24 hours, contact your healthcare provider. Severe dehydration from vomiting is the most common pathway to kidney complications.
Managing Constipation (24% of patients)
Increase water intake to at least 64 ounces daily. Add fiber gradually through vegetables, fruits, and whole grains, but do not overload on fiber all at once, as this can worsen bloating. A daily psyllium husk supplement or MiraLAX can help keep things moving.
Regular physical activity, especially walking, is also effective.
How Do Wegovy Side Effects Change During Dose Escalation?
Wegovy follows a 5-step dose-escalation schedule over 16 to 20 weeks, specifically designed to minimize side effects. In the STEP-1 trial (NCT03548935), the majority of GI adverse events occurred during the escalation phase and decreased once patients stabilized on the 2.4mg maintenance dose. Each dose increase carries a temporary spike in symptoms as the body adjusts to stronger GLP-1 receptor activation.
| Dose | Duration | Expected GI Symptoms | Clinical Notes |
|---|---|---|---|
| 0.25mg | Weeks 1 to 4 | Mild nausea in some patients | Sub-therapeutic dose for titration only |
| 0.5mg | Weeks 5 to 8 | Nausea increases, mild diarrhea possible | First noticeable appetite reduction for most |
| 1.0mg | Weeks 9 to 12 | GI symptoms peak for many patients | Many patients report this as the hardest transition |
| 1.7mg | Weeks 13 to 16 | Moderate symptoms, improving from 1.0mg transition | Significant appetite suppression and early weight loss |
| 2.4mg | Week 17 onward | Nausea 44%, diarrhea 30%, vomiting 24% (total trial rates) | Maintenance dose, side effects gradually improve with continued use |
If you cannot tolerate a dose increase, your provider can extend the current dose for an additional 4 weeks before trying again. Some providers also use half-step increases (for example, alternating between the current and next dose weekly) to ease the transition. Do not skip doses or try to escalate faster than recommended, as both approaches tend to worsen side effects.
Wegovy Side Effects vs Zepbound Side Effects: How Do They Compare?
Zepbound (tirzepatide) and Wegovy (semaglutide) target the same patient population, but their side effect profiles differ. Based on data from STEP-1 (NCT03548935) and SURMOUNT-1 (NCT04184622), Wegovy consistently shows higher rates of GI side effects across nearly every category. The GI discontinuation rate for Wegovy (~7%) is also roughly double that of Zepbound (~4.3%).
| Side Effect | Wegovy 2.4mg (STEP-1) | Zepbound 15mg (SURMOUNT-1) | Difference |
|---|---|---|---|
| Nausea | 44% | 29% | Wegovy 15 points higher |
| Diarrhea | 30% | 21% | Wegovy 9 points higher |
| Vomiting | 24% | 13% | Wegovy 11 points higher |
| Constipation | 24% | 11% | Wegovy 13 points higher |
| Headache | 14% | ~5% | Wegovy notably higher |
| Gallbladder events | 2.6% | ~1.5% | Wegovy modestly higher |
| GI discontinuation | ~7% | ~4.3% | Wegovy nearly double |
| Weight loss (max dose) | ~14.9% | ~22.5% | Zepbound significantly greater |
The difference in tolerability may come from Zepbound's dual GIP/GLP-1 mechanism. GIP receptor activation may partially buffer the GI effects of GLP-1 agonism. However, individual responses vary widely, and some patients tolerate Wegovy better than Zepbound.
Important caveat: these numbers come from separate trials, not a head-to-head study. The ongoing SURMOUNT-5 trial is designed to directly compare tirzepatide and semaglutide, and its results will provide more definitive answers.
For a detailed breakdown of Zepbound's side effect data, see our Zepbound side effects guide. For help choosing between medications, check our best GLP-1 medications without insurance comparison.
Frequently Asked Questions About Wegovy Side Effects
How long do Wegovy side effects last?
Most GI side effects peak during the dose-escalation phase (first 16 to 20 weeks) and improve once you stabilize on the 2.4mg maintenance dose. In the STEP-1 trial (NCT03548935), the majority of GI events were transient and classified as mild to moderate. Many patients report significant improvement by month 4 to 5 of treatment.
Does Wegovy cause hair loss?
Hair thinning was reported in approximately 3% of STEP-1 participants. Like other weight-loss treatments, this is most likely telogen effluvium triggered by rapid weight loss and caloric deficit rather than a direct drug effect. Hair growth typically normalizes 9 to 12 months after weight stabilization.
Ensuring adequate protein intake (0.8 to 1g per pound of lean body mass) can help minimize shedding.
Is Wegovy safe for long-term use?
The STEP-5 extension trial followed patients on Wegovy for 2 years and found a consistent safety profile with no new safety signals emerging over time. GI side effects decreased with continued use. Long-term cardiovascular data from the SELECT trial (NCT03574597) also showed semaglutide reduced major cardiovascular events by 20%, providing additional safety reassurance.
Can Wegovy cause gallstones?
Yes. Gallbladder events including gallstones occurred in 2.6% of STEP-1 participants on Wegovy versus 1.2% on placebo. Rapid weight loss itself is a known risk factor for gallstones.
Your risk is highest during the first 6 to 12 months of treatment when weight loss is most rapid. Symptoms include upper right abdominal pain, nausea, and fever.
What happens if I miss a Wegovy dose?
If you miss a dose and your next scheduled dose is more than 2 days away, take the missed dose as soon as possible. If the next dose is within 2 days, skip the missed dose and resume your regular schedule. Do not take two doses to make up for a missed one.
Missing multiple doses may temporarily increase GI side effects when you resume.
Does Wegovy interact with other medications?
Wegovy slows gastric emptying, which can affect the absorption of oral medications. This is particularly relevant for birth control pills, antibiotics, and medications with narrow therapeutic windows. Take time-sensitive oral medications at least 1 hour before your Wegovy injection day or discuss timing adjustments with your pharmacist.
Can I take Wegovy if I have thyroid problems?
Wegovy is contraindicated only in patients with medullary thyroid carcinoma (MTC) or MEN 2 syndrome. Common thyroid conditions like hypothyroidism (treated with levothyroxine) are not a contraindication. However, since semaglutide slows gastric emptying, you may need to adjust when you take thyroid medication.
Discuss timing with your provider.
When should I go to the ER for Wegovy side effects?
Go to the emergency room if you experience severe abdominal pain that does not resolve with rest, inability to keep any fluids down for more than 24 hours, signs of severe allergic reaction (facial swelling, throat tightness, difficulty breathing), symptoms of kidney failure (very dark urine, no urination, severe swelling), or persistent chest pain. These may indicate pancreatitis, severe dehydration, anaphylaxis, or other emergencies.